Finicky formulary committees and rising consumer cost consciousness add up to a new market dynamic for health brands. A new survey helps break it down.
UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth
The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices
Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.
Drugmakers face increasing pressure on pricing from insurers and PBMs.
A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
A look at the content that grabbed most reader interest over the past year.
If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.
Official numbers are pending, but Reuters notes enrollment appears to be just 3% of the government's goal.
AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011
Allergan asks FDA to reconsider Restatis generics requirements, Incyte's Jakafi could be pancreatic cancer nemesis, Medtronic says its strategy is at the heart of where healthcare is going and Aetna's app alliance makes health local and personal.
A new survey of doctors reveals how much they know (or don't) about the looming launch of healthcare exchanges.
A study highlights medical service trends among patients with high-deductible plans but lacks insight on health impact and long-term costs.
Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.
AstaZeneca avoids a Lipitor moment, FDA approves Novartis med for Cushing's, and Teva ventures into South Korea. Plus: a closer look at health exchanges
The Department of Health and Human Services observed the anniversary of the September 11, 2001 attacks by extending coverage of a program for first responders sickened by their work at Ground Zero, the Pentagon and the Flight 93 crash site in Shanksville, PA to cover some 50 cancers.
The Institute of Medicine has released a report putting the cost of unnecessary medical care at $750 billion a year and counting. What does it mean for pharmas? Depends on how you read it.
Pharma needs to step up its sales pitch, looking beyond a drug's top attributes, to convince payers that their drugs are worth the cost.